View More View Less
  • 1 Honvédkórház-Állami Egészségügyi Központ II. Belgyógyászati Osztály Budapest Podmaniczky u. 109–111. 1062
Restricted access

A humán növekedési hormon és a növekedésihormon-receptor szerkezetének részletes felderítése, valamint interakciójuk pontos megismerése lehetővé tette egy újabb hatásmechanizmusú fehérje, a növekedésihormonreceptor-antagonista, a pegvisomant kifejlesztését. Ezzel bővült az acromegalia kezelésére alkalmazható gyógyszercsoportok köre. Ennek jelentőségét az adja, hogy a betegség mortalitását tekintve bizonyított a növekedési hormon/inzulinszerű növekedési faktor-I tengely szigorúbb kontrolljának szükségessége, valamint hogy az eddig rendelkezésünkre álló terápiás lehetőségek (műtét, radioterápia, dopaminagonista, szomatosztatinanalóg) alkalmazása ellenére a betegek jelentős része nem megfelelően kontrollált. A pegvisomant 2004-ben került törzskönyvezésre. 2006-tól hazánkban is alkalmazzák olyan acromegaliás betegek kezelésére, akiknél a műtét és/vagy besugárzás nem volt kielégítő hatású, és akiknél a szomatosztatinanalógokkal való kezelés hatására nem normalizálódott az inzulinszerű növekedési faktor-I koncentrációja és a növekedésihormon-érték nem került a kívánt tartományba, vagy a kezelést nem tolerálták. A pegvisomant klinikai alkalmazása eredményes, jól tolerálható és biztonságos a nemzetközi adatbázis (Acrostudy) eredményei alapján. A kezelés eredményességének további növelése céljából számos nemzetközi vizsgálatot végeztek a szomatosztatinanalógok és a pegvisomant együttes adásával. A növekedési hormon/inzulinszerű növekedési faktor-I tengely egyéb hatásainak ismeretében a növekedésihormonreceptor-antagonistának további alkalmazási lehetőségei is a kutatás tárgyát képezik. Orv. Hetil., 2011, 152, 709–714.

  • Yang, N., Langenheim, J. F., Wang, X. és mtsai: Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insight into receptor triggering. Mol. Endocrinol., 2008, 22, 978–988.

    Wang X. , 'Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insight into receptor triggering ' (2008 ) 22 Mol. Endocrinol. : 978 -988.

    • Search Google Scholar
  • Kopchick, J. J., Parkinson, C., Stevens, E. C. és mtsai: Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev., 2002, 23, 623–646.

    Stevens E. C. , 'Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly ' (2002 ) 23 Endocr. Rev. : 623 -646.

    • Search Google Scholar
  • Kopchick, J. J.: Discovery and mechanism of action of pegvisomant. Eur. J. Endocrinol., 2003, 148, S21–S25.

    Kopchick J. J. , 'Discovery and mechanism of action of pegvisomant ' (2003 ) 148 Eur. J. Endocrinol. : S21 -S25.

    • Search Google Scholar
  • Higham, C. E., Trainer, P. J.: Growth hormone excess and the development of growth hormone receptor antagonists. Exp. Physiol., 2008, 93, 1157–1169.

    Trainer P. J. , 'Growth hormone excess and the development of growth hormone receptor antagonists ' (2008 ) 93 Exp. Physiol. : 1157 -1169.

    • Search Google Scholar
  • Roelfsema, F., Biermasz, N. R., Pereira, A. M. és mtsai: Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int. J. Nanomed., 2006, 1, 385–398.

    Pereira A. M. , 'Nanomedicines in the treatment of acromegaly: focus on pegvisomant ' (2006 ) 1 Int. J. Nanomed. : 385 -398.

    • Search Google Scholar
  • Maamra, M., Kopchick, J. J., Strasburger, C. J. és mtsai: Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalisation. J. Clin. Endocrinol., 2004, 89, 4532–4537.

    Strasburger C. J. , 'Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalisation ' (2004 ) 89 J. Clin. Endocrinol. : 4532 -4537.

    • Search Google Scholar
  • Debono, M., Newell-Price, J.: New formulations and approaches in the medical treatment of acromegaly. Curr. Opin. Endocrinol. Diabetes Obes., 2010, 17, 350–355.

    Newell-Price J. , 'New formulations and approaches in the medical treatment of acromegaly ' (2010 ) 17 Curr. Opin. Endocrinol. Diabetes Obes. : 350 -355.

    • Search Google Scholar
  • Trainer, P. J., Drake, W. M., Katznelson, L. és mtsai: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med., 2000, 42, 1171–1177.

    Katznelson L. , 'Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant ' (2000 ) 42 N. Engl. J. Med. : 1171 -1177.

    • Search Google Scholar
  • Van der Lely, A. J., Hutson, R. K., Trainer, P. J. és mtsai: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 2001, 358, 1754–1759.

    Trainer P. J. , 'Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist ' (2001 ) 358 Lancet : 1754 -1759.

    • Search Google Scholar
  • Schreiber, I., Buchfelder, M., Droste, M. és mtsai: Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety, and efficacy evaluation from the German Pegvisomant Observatory Study. Eur. J. Endocrinol., 2007, 156, 75–82.

    Droste M. , 'Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety, and efficacy evaluation from the German Pegvisomant Observatory Study ' (2007 ) 156 Eur. J. Endocrinol. : 75 -82.

    • Search Google Scholar
  • Buchfelder, M., Schlaffer, S., Droste, M. és mtsai: The German Acrostudy: past and present. Eur. J. Endocrinol., 2009, 161, S3–S10.

    Droste M. , 'The German Acrostudy: past and present ' (2009 ) 161 Eur. J. Endocrinol. : S3 -S10.

    • Search Google Scholar
  • Bernabeu, I., Cameselle-Teijeiro, J., Casanueva, F. F. és mtsai: Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert’s syndrome. Eur. J. Endocrinol., 2009, 160, 869–872.

    Casanueva F. F. , 'Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert’s syndrome ' (2009 ) 160 Eur. J. Endocrinol. : 869 -872.

    • Search Google Scholar
  • Bernabeu, I., Marazuela, M., Lucas, T. és mtsai: Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome. J. Clin. Endocrinol. Metab., 2010, 95, 2147–2154.

    Lucas T. , 'Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert’s syndrome ' (2010 ) 95 J. Clin. Endocrinol. Metab. : 2147 -2154.

    • Search Google Scholar
  • Trainer, P. J.: Acrostudy: an overview. Horm. Res., 2007, 68, 68–69.

    Trainer P. J. , 'Acrostudy: an overview ' (2007 ) 68 Horm. Res. : 68 -69.

  • Brue, T., Castinetti, F., Lundgren, F. és mtsai: Which patients with acromegaly are treated with pegvisomant? An overview of methology and baseline data in acrostudy. Eur. J. Endocrinol., 2009, 161, S11–S17.

    Lundgren F. , 'Which patients with acromegaly are treated with pegvisomant? An overview of methology and baseline data in acrostudy ' (2009 ) 161 Eur. J. Endocrinol. : S11 -S17.

    • Search Google Scholar
  • Brue, T.: Acrostudy: Status Update on 469 Patients. Horm. Res., 2009, 1, S34–S38.

    Brue T. , 'Acrostudy: Status Update on 469 Patients ' (2009 ) 1 Horm. Res. : S34 -S38.

  • Trainer, P. J.: Acrostudy: the first 5 years. Eur. J. Endocrinol., 2009, 161, S19–S24.

    Trainer P. J. , 'Acrostudy: the first 5 years ' (2009 ) 161 Eur. J. Endocrinol. : S19 -S24.

  • Jimenez, C., Burman, P., Abs, R. és mtsai: Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur. J. Endocrinol., 2008, 159, 517–523.

    Abs R. , 'Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials ' (2008 ) 159 Eur. J. Endocrinol. : 517 -523.

    • Search Google Scholar
  • Buhk, J. H., Jung, S., Psychogios, M. N. és mtsa: Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J. Clin. Endocrinol. Metab., 2010, 95, 552–558.

    Psychogios M. N. , 'Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study ' (2010 ) 95 J. Clin. Endocrinol. Metab. : 552 -558.

    • Search Google Scholar
  • Brian, S. R., Bidlingmaier, M., Wajnrajch, M. P. és mtsai: Clinical case seminar. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J. Clin. Endocrinol. Metab., 2007, 92, 3374–3377.

    Wajnrajch M. P. , 'Clinical case seminar. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects ' (2007 ) 92 J. Clin. Endocrinol. Metab. : 3374 -3377.

    • Search Google Scholar
  • Higham, C. E., Thomas, J. D., Bidlingmaier, M. és mtsai: Successful use of weekly pegvisomant administration in patients with acromegaly. Eur. J. Endocrinol., 2009, 161, 21–25.

    Bidlingmaier M. , 'Successful use of weekly pegvisomant administration in patients with acromegaly ' (2009 ) 161 Eur. J. Endocrinol. : 21 -25.

    • Search Google Scholar
  • Marazuela, M., Daudén, E., Ocón, E. és mtsai: Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann. Intern. Med., 2007, 147, 741–743.

    Ocón E. , 'Pegvisomant-induced lipohypertrophy: report of a case with histopathology ' (2007 ) 147 Ann. Intern. Med. : 741 -743.

    • Search Google Scholar
  • Neggers, S. J., van Aken, M. O., de Herder, W. W. és mtsai: Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab., 2008, 93, 3853–3859.

    Herder W. W. , 'Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant ' (2008 ) 93 J. Clin. Endocrinol. Metab. : 3853 -3859.

    • Search Google Scholar
  • Feenstra, J., de Herder, W. W., ten Have, S. M. és mtsai: Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 2005, 365, 1644–1646.

    Have S. M. , 'Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly ' (2005 ) 365 Lancet : 1644 -1646.

    • Search Google Scholar
  • Neggers, S. J., van Aken, M. O., Janssen, J. A. és mtsai: Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab., 2007, 92, 4598–4601.

    Janssen J. A. , 'Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly ' (2007 ) 92 J. Clin. Endocrinol. Metab. : 4598 -4601.

    • Search Google Scholar
  • Neggers, S. J., van der Lely, A. J.: Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat. Rev. Endocrinol., 2009, 5, 546–552.

    Lely A. J. , 'Somatostatin analog and pegvisomant combination therapy for acromegaly ' (2009 ) 5 Nat. Rev. Endocrinol. : 546 -552.

    • Search Google Scholar
  • Neggers, S. J., de Herder, W. W., Janssen, J. A. és mtsai: Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol., 2009, 160, 529–533.

    Janssen J. A. , 'Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients ' (2009 ) 160 Eur. J. Endocrinol. : 529 -533.

    • Search Google Scholar
  • Neggers, S. J., de Herder, W. W., Feelders, R. A. és mtsa: Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary, 2011. (Epub ahead of print.)

  • Van der Lely, A. J., Bernabeu, I., Cap, J. és mtsai: Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol., 2011, 164, 325–333.

    Cap J. , 'Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone ' (2011 ) 164 Eur. J. Endocrinol. : 325 -333.

    • Search Google Scholar
  • Neggers, S. J., Kopchick, J. J., Jørgensen, J. O. és mtsai: Hypothesis: Extra-hepatic acromegaly: a new paradigm? Eur. J. Endocrinol., 2011, 164, 11–16.

    Jørgensen J. O. , 'Hypothesis: Extra-hepatic acromegaly: a new paradigm? ' (2011 ) 164 Eur. J. Endocrinol. : 11 -16.

    • Search Google Scholar
  • Laban, C., Bustin, S. A., Jenkins, P. J.: The GH-IGF-I axis and breast cancer. Trends. Endocrinol. Metab., 2003, 14, 28–34.

    Jenkins P. J. , 'The GH-IGF-I axis and breast cancer ' (2003 ) 14 Trends. Endocrinol. Metab. : 28 -34.

    • Search Google Scholar
  • Weiss-Messer, E., Merom, O., Adia, A. és mtsai: Growth hormone (GH) receptor in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol. Cell. Endocrinol., 2004, 220, 109–123.

    Adia A. , 'Growth hormone (GH) receptor in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells ' (2004 ) 220 Mol. Cell. Endocrinol. : 109 -123.

    • Search Google Scholar
  • Pollak, M. N., Schemhammer, E. S., Hankinson, S. E.: Insuline-like growth factors and neoplasia. Nat. Rev. Cancer., 2004, 4, 505–518.

    Hankinson S. E. , 'Insuline-like growth factors and neoplasia ' (2004 ) 4 Nat. Rev. Cancer. : 505 -518.

    • Search Google Scholar
  • Yang, X., Liu, F., Xu, Z. és mtsai: Growth hormone receptor expression in human colorectal cancer. Dig. Dis. Sci., 2004, 49, 1493–1498.

    Xu Z. , 'Growth hormone receptor expression in human colorectal cancer ' (2004 ) 49 Dig. Dis. Sci. : 1493 -1498.

    • Search Google Scholar
  • Yin, D., Vreeland, F., Schaaf, L. J. és mtsai: Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin. Cancer. Res., 2007, 13, 1000–1009.

    Schaaf L. J. , 'Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy ' (2007 ) 13 Clin. Cancer. Res. : 1000 -1009.

    • Search Google Scholar
  • Zatelli, M. C., Minoia, M., Molè, D. és mtsai: Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab., 2009, 94, 3931–3938.

    Molè D. , 'Growth hormone excess promotes breast cancer chemoresistance ' (2009 ) 94 J. Clin. Endocrinol. Metab. : 3931 -3938.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 13 0 1
Feb 2021 21 2 4
Mar 2021 5 0 0
Apr 2021 5 0 1
May 2021 10 0 0
Jun 2021 12 0 0
Jul 2021 0 0 0